{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:51:34Z","timestamp":1791150694952,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06840-0","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:20:15Z","timestamp":1790875215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surrogacy of intermediate clinical endpoints for overall survival in BCG-na\u00efve high-risk non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Longoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Occhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zaurito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tremolada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Claps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Grobet-Jeandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Rodriguez Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Lafuente Puentedura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ca\u00f1o Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Hurle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Ottone","family":"Cirulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Naspro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the European Association of Urology -Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"6","key":"6840_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O et al (2024) European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update. Eur Urol 86(6):531\u2013549. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027","journal-title":"Eur Urol"},{"issue":"1","key":"6840_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.euf.2025.04.033","volume":"12","author":"P Scilipoti","year":"2026","unstructured":"Scilipoti P, Longoni M, de Angelis M et al (2026) Long-term oncological outcomes for patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin (BCG): a comparative analysis of adequate versus inadequate BCG treatment. Eur Urol Focus 12(1):70\u201378. https:\/\/doi.org\/10.1016\/j.euf.2025.04.033","journal-title":"Eur Urol Focus"},{"issue":"5","key":"6840_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/bju.16780","volume":"136","author":"M Longoni","year":"2025","unstructured":"Longoni M, Scilipoti P, De Angelis M et al (2025) Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study. BJU Int 136(5):826\u2013834. https:\/\/doi.org\/10.1111\/bju.16780","journal-title":"BJU Int"},{"issue":"4","key":"6840_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2004","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V et al (2004) European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 79(4):480\u2013488. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033","journal-title":"Eur Urol"},{"issue":"5","key":"6840_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","volume":"8","author":"M Longoni","year":"2025","unstructured":"Longoni M, Scilipoti P, Soria F et al (2025) Oncological outcomes in Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives. Eur Urol Oncol 8(5):1375\u20131392. https:\/\/doi.org\/10.1016\/j.euo.2025.03.007","journal-title":"Eur Urol Oncol"},{"key":"6840_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70231","author":"A \u015alusarczyk","year":"2026","unstructured":"\u015alusarczyk A, Scilipoti P, Contieri R et al (2026) Refining BCG-failure classifications in non-muscle-invasive bladder cancer. BJU Int. https:\/\/doi.org\/10.1111\/bju.70231","journal-title":"BJU Int"},{"issue":"1","key":"6840_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","volume":"24","author":"TR Fleming","year":"2005","unstructured":"Fleming TR (2005) Surrogate endpoints and FDA\u2019s accelerated approval process. Health Aff (Millwood) 24(1):67\u201378. https:\/\/doi.org\/10.1377\/hlthaff.24.1.67","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"6840_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.eururo.2025.12.022","volume":"89","author":"P Scilipoti","year":"2026","unstructured":"Scilipoti P, Zaurito P, Longoni M et al (2026) Efficacy and safety of checkpoint inhibitors combined with Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve high-risk non-muscle-invasive bladder cancer: synthesis of evidence from the ALBAN, CREST, and POTOMAC trials. Eur Urol 89(3):204\u2013209. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.022","journal-title":"Eur Urol"},{"key":"6840_CR9","unstructured":"U.S. Food and Drug Administration. FDA-BCAN Workshop: Endpoints for the Development of Neoadjuvant Systemic Therapy Regimens for Muscle-Invasive Bladder Cancer. News & Events for Human Drugs. August 8, 2019. Accessed Jan 30, 2026. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-bcan-workshop-endpoints-development-neoadjuvant-systemic-therapy-regimens-muscle-invasive"},{"issue":"3","key":"6840_CR10","doi-asserted-by":"publisher","first-page":"69.e17","DOI":"10.1016\/j.urolonc.2024.01.001","volume":"42","author":"A Porreca","year":"2024","unstructured":"Porreca A, Di Nicola M, Lucarelli G et al (2024) Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: results from a machine learning-based analysis of a large multi-institutional database. Urol Oncol 42(3):69.e17-69.e25. https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.001","journal-title":"Urol Oncol"},{"issue":"4","key":"6840_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","volume":"8","author":"RL Prentice","year":"1989","unstructured":"Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8(4):431\u2013440. https:\/\/doi.org\/10.1002\/sim.4780080407","journal-title":"Stat Med"},{"issue":"1","key":"6840_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","volume":"1","author":"M Buyse","year":"2000","unstructured":"Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1(1):49\u201367. https:\/\/doi.org\/10.1093\/biostatistics\/1.1.49","journal-title":"Biostatistics"},{"issue":"3","key":"6840_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1017\/S0266462314000300","volume":"30","author":"O Ciani","year":"2014","unstructured":"Ciani O, Davis S, Tappenden P et al (2014) Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care 30(3):312\u2013324. https:\/\/doi.org\/10.1017\/S0266462314000300","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"6840_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bju.16675","volume":"136","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti P, Longoni M, de Angelis M et al (2025) Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer. BJU Int 136(1):47\u201354. https:\/\/doi.org\/10.1111\/bju.16675","journal-title":"BJU Int"},{"issue":"4","key":"6840_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat AM, Flaig TW, Grossman HB et al (2015) Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 12(4):225\u2013235. https:\/\/doi.org\/10.1038\/nrurol.2015.58","journal-title":"Nat Rev Urol"},{"issue":"5","key":"6840_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.7326\/M18-2782","volume":"170","author":"HB Bentzen","year":"2019","unstructured":"Bentzen HB, H\u00f8stm\u00e6lingen N (2019) Balancing protection and free movement of personal data: the new European Union General Data Protection Regulation. Ann Intern Med 170(5):335\u2013337. https:\/\/doi.org\/10.7326\/M18-2782","journal-title":"Ann Intern Med"},{"key":"6840_CR17","unstructured":"U.S. Food and Drug Administration (2018) Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. Accessed Apr 13, 2026. https:\/\/www.fda.gov\/media\/71195\/download"},{"issue":"3","key":"6840_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","volume":"75","author":"M Assel","year":"2019","unstructured":"Assel M, Sjoberg D, Elders A et al (2019) Guidelines for reporting of statistics for clinical research in urology. Eur Urol 75(3):358\u2013367. https:\/\/doi.org\/10.1016\/j.eururo.2018.12.014","journal-title":"Eur Urol"},{"issue":"12","key":"6840_CR19","doi-asserted-by":"publisher","first-page":"451.e1","DOI":"10.1016\/j.urolonc.2024.06.026","volume":"42","author":"P Scilipoti","year":"2024","unstructured":"Scilipoti P, Longoni M, de Angelis M et al (2024) Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center. Urol Oncol 42(12):451.e1-451.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.026","journal-title":"Urol Oncol"},{"issue":"2","key":"6840_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","volume":"8","author":"J Taylor","year":"2025","unstructured":"Taylor J, Kamat AM, Annapureddy D et al (2025) Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with bacillus Calmette-Gu\u00e9rin in patients with bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer. Eur Urol Oncol 8(2):469\u2013476. https:\/\/doi.org\/10.1016\/j.euo.2024.12.005","journal-title":"Eur Urol Oncol"},{"key":"6840_CR21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.7014","author":"P Scilipoti","year":"2026","unstructured":"Scilipoti P, de Angelis M, Thibault C et al (2026) Surrogacy of intermediate clinical endpoints for overall survival in patients with localized muscle-invasive bladder cancer. J Natl Compr Canc Netw. https:\/\/doi.org\/10.6004\/jnccn.2026.7014. (Published online June 16, 2026)","journal-title":"J Natl Compr Canc Netw"},{"issue":"31","key":"6840_CR22","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","volume":"31","author":"S Halabi","year":"2013","unstructured":"Halabi S, Armstrong AJ, Sartor O et al (2013) Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol 31(31):3944\u20133950. https:\/\/doi.org\/10.1200\/JCO.2013.50.3201","journal-title":"J Clin Oncol"},{"issue":"12","key":"6840_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv261","volume":"107","author":"C Sweeney","year":"2015","unstructured":"ICECaP Working Group, Sweeney C, Nakabayashi M et al (2015) The development of intermediate clinical endpoints in cancer of the prostate (ICECaP). J Natl Cancer Inst 107(12):djv261. https:\/\/doi.org\/10.1093\/jnci\/djv261. (Published 2015 Sep 25)","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"6840_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/0962280207082719","volume":"17","author":"MN Lassere","year":"2008","unstructured":"Lassere MN (2008) The Biomarker-Surrogacy evaluation schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 17(3):303\u2013340","journal-title":"Stat Methods Med Res"},{"key":"6840_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.03.020","author":"M Moschini","year":"2026","unstructured":"Moschini M, Mir MC, Aning J, Volpe A, EAU Oncology Section (2026) Immunotherapy escalation in BCG-na\u00efve NMIBC: time for selectivity, not enthusiasm. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2026.03.020","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"6840_CR26","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","volume":"30","author":"A \u015alusarczyk","year":"2023","unstructured":"\u015alusarczyk A, Zapa\u0142a P, Zapa\u0142a \u0141, Borkowski T, Radziszewski P (2023) Cancer-specific survival of patients with non-muscle-invasive bladder cancer: a population-based analysis. Ann Surg Oncol 30(12):7892\u20137902. https:\/\/doi.org\/10.1245\/s10434-023-14051-9","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"6840_CR27","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bju.16645","volume":"135","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti P, Longoni M, de Angelis M et al (2025) Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. BJU Int 135(6):969\u2013976. https:\/\/doi.org\/10.1111\/bju.16645","journal-title":"BJU Int"},{"issue":"1","key":"6840_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-04970-x","volume":"42","author":"F Pellegrino","year":"2024","unstructured":"Pellegrino F, Leni R, Basile G et al (2024) Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center. World J Urol 42(1):270. https:\/\/doi.org\/10.1007\/s00345-024-04970-x","journal-title":"World J Urol"},{"issue":"6","key":"6840_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.eururo.2024.08.001","volume":"86","author":"R Li","year":"2024","unstructured":"Li R, Hensley PJ, Gupta S et al (2024) Bladder-sparing therapy for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: international bladder cancer group recommendations for optimal sequencing and patient selection. Eur Urol 86(6):516\u2013527. https:\/\/doi.org\/10.1016\/j.eururo.2024.08.001","journal-title":"Eur Urol"},{"issue":"3","key":"6840_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70220","volume":"132","author":"R Bhattacharya","year":"2026","unstructured":"Bhattacharya R, Kponee-Shovein K, Gao Y et al (2026) Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: a meta-analysis of bacillus Calmette-Gu\u00e9rin-naive or -remote cases. Cancer 132(3):e70220. https:\/\/doi.org\/10.1002\/cncr.70220","journal-title":"Cancer"},{"issue":"4","key":"6840_CR31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124\u20131129","journal-title":"J Urol"},{"issue":"8","key":"6840_CR32","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore ND, Powles TB, Bedke J et al (2025) Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med 31(8):2806\u20132814. https:\/\/doi.org\/10.1038\/s41591-025-03738-z","journal-title":"Nat Med"},{"issue":"1","key":"6840_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","volume":"37","author":"M Roupret","year":"2026","unstructured":"Roupret M, Bertaut A, Pignot G et al (2026) ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Ann Oncol 37(1):44\u201352. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017","journal-title":"Ann Oncol"},{"issue":"10516","key":"6840_CR34","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","volume":"406","author":"M De Santis","year":"2025","unstructured":"De Santis M, Palou Redorta J, Nishiyama H et al (2025) Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet 406(10516):2221\u20132234. https:\/\/doi.org\/10.1016\/S0140-6736(25)01897-5","journal-title":"Lancet"},{"key":"6840_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.06.006","author":"P Scilipoti","year":"2026","unstructured":"Scilipoti P, \u015alusarczyk A, Thibault C et al (2026) Evaluating the surrogacy of pathological complete response at radical cystectomy in neoadjuvant-based muscle-invasive bladder cancer trials. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2026.06.006. (Published online June 25, 2026)","journal-title":"Eur Urol Oncol."}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06840-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06840-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06840-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:01:45Z","timestamp":1791147705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06840-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6840"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06840-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"4 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no conflict of interest related to this study to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data collection followed the principles of the Declaration of Helsinki. All participants provided informed consent to share their anonymized data for future research.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"721"}}